EMA’s Emer Cooke On The Future Of Rolling Reviews & The End Of Remote Meetings
Executive Summary
Emer Cooke, executive director of the European Medicines Agency, has offered some insights into how the agency’s working may change following the COVID-19 pandemic, including the development of hybrid inspections.
You may also be interested in...
Pandemic Drives Rise In EMA Scientific Advice, But New EU Drug Filings Slow
The European Medicines Agency is expecting a lively pipeline of advanced therapy medicines over the next few years. It is also making final preparations for the introduction of the new EU clinical trials system from the end of January next year.
Breakthrough Agreement On EU HTA Regulation “Falls Short”
The European Parliament and EU Council have reached an agreement on taking forward proposals for greater cooperation on health technology assessments.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.